MTOR and prostate cancer: Both AKT‐mTOR and androgen receptor (AR) signaling pathways are aberrantly activated in prostate cancer due to PTEN deletion or SPOP mutation, two genetic lesions occurring in up to 80% of advanced prostate cancer.